Objectives: The aim of this study was to determine a robust (sensitive and objective) method for analyzing renal blood oxygenation level-dependent magnetic resonance imaging data. Materials and Methods: Forty-seven subjects (30 with chronic kidney disease [CKD] and 17 controls) were imaged at baseline and after furosemide with a multiecho gradient recalled echo sequence. Conventional analysis consisted of regional segmentation (small cortex, large cortex, and medulla), followed by computing the mean of each region. In addition, we segmented the entire parenchyma and computed the mean (μ 1 ) plus higher moments (μ 2 , μ 3 , and μ 4 ). Two raters performed each of the segmentation steps, and agreement was assessed with intraclass correlation coefficients (ICCs). We used a measure of effect size (Cohen's d value), in addition to the usual measure of statistical significance, P values, for determining significant results. Results: The mean of the renal parenchyma showed the highest agreement between raters (ICC, 0.99), and the higher parenchyma moments were on par with large cortical region of interest (ROI) ICC. The renal parenchymal mean also exhibited significant sensitivity to changes after furosemide administration in healthy subjects (P = 0.002, d = 0.84), in agreement with medullary ROIs (P = 0.002, d = 1.59). When comparing controls and subjects with CKD at baseline, cortical ROI showed a significant difference (P = 0.015, d = −0.69), whereas the parenchyma ROI did not (P = 0.152, d = 0.39). Post-furosemide data in all regions resulted in a significant difference (large cortex: P = 0.026, d = −0.51; medulla: P = 0.019, d = −0.61) with the renal parenchyma ROI resulting in the largest effect size (P = 0.003, d = −0.75). Higher moments of the renal parenchyma showed similar significant differences as well. Conclusions: Overall, our data support the use of the entire parenchyma to evaluate changes in the medulla after administration of furosemide, a widely used pharmacological maneuver. Changes in higher moments indicate that there is more than just a shift in the mean renal R2* and may provide clinically relevant information without the need for subjective regional segmentation. For evaluating differences between controls and subjects with CKD at baseline; large cortical ROI provided the highest sensitivity and objectivity. A combination of renal parenchyma assessment and large cortical ROI may provide the most robust method of evaluating renal blood oxygenation level-dependent magnetic resonance imaging data.
R
enal hypoxia is thought to play a key role in the progression of chronic kidney disease (CKD), 1, 2 leading to an interest in noninvasive assessment of renal oxygenation. Renal blood oxygenation leveldependent (BOLD) magnetic resonance imaging (MRI) is currently the only known noninvasive method that can be used to evaluate renal oxygenation in humans. 3, 4 Extensive research has shown that this technique has the ability to detect intrasubject changes after various interventions. 3, [5] [6] [7] There is a growing interest in applying this method to distinguish different groups of subjects, such as those with CKD, as compared with control subjects. [8] [9] [10] [11] However, experience to date has led to conflicting reports on whether renal BOLD can detect differences between controls and subjects with CKD. Nonuniform hydration status between subjects, varied oxygenation due to multiple etiologies, and a variation in medication among the subjects may at least in part explain some of the discrepancies. 12 In addition, the method of analysis may play a role. 10 Renal BOLD MRI studies have predominantly used the mean value of small, manually defined regions of interest (ROI) within the cortex and medulla. This technique is useful for cases where the renal cortex and medulla are readily discernible, such as at baseline in healthy subjects. However, the contrast may not be sufficient to distinguish the two regions in patients with CKD or even healthy subjects after furosemide administration. 7 It is known that cortico-medullary contrast decreases in advanced CKD, making this technique suboptimal for analyzing such cases. 13 Recent studies have indicated the subjectivity of this regional segmentation technique, and a few methods to overcome the limitations have been proposed. [14] [15] [16] There is an inherent heterogeneity in the distribution of R2* values even within each of the two different renal tissues. 17 Researchers have attempted to reduce this variation by defining several ROIs and taking the average of their means as a measure of R2* for each region. 18 Alternately, in the cortex, it is possible to define a large ROI that acts as an average across the entire region.
A method that minimizes the subjectivity of ROI placement in renal BOLD analysis will be especially important for comparing data from different institutions and establishing renal BOLD MRI as a clinically viable technique. 19 One method of addressing these issues is through histogram analysis of the renal parenchyma. Histogram analysis has been effectively applied to diffusion maps in the cervical cord of multiple sclerosis patients, 20 diffusion images for intracranial tumor differentiation 21 and renal tumor classification, 22 and more recently to arterial spin labeled images of mild CKD patients. 23 Based on this general principle, we have tested the hypothesis that a method that analyzes the R2* distribution of the entire renal parenchyma will be able to detect quantitative changes in subjects after interventions and between groups of subjects with different levels of kidney function. Because of the mixed distribution of tissues within the parenchyma when taken as a whole entity, the renal R2* distribution will not be normally distributed. This implies that the mean and standard deviation (first two moments) may not be sufficient to fully represent the actual distribution. We have explored the use of two additional moments for characterizing this distribution. Although our method is related to histogram analysis, it does not require a bin size and assumes nothing about the distribution of values. Furthermore, we utilize a kernel density estimate of the empirical distribution when displaying the distributions, as it does not require a bin size as well. Hence forth, our method will be referred to as moment analysis.
To determine a robust (sensitive and objective) method for analyzing renal BOLD MRI data, we have evaluated the ability of conventional BOLD analysis and parenchyma moment analysis to detect intersubject and intrasubject differences in controls and subjects with CKD. Specifically, we have evaluated the interrater agreement, sensitivity to changes after administration of furosemide, and the relative sensitivity of the methods in differentiating controls from subjects with CKD.
MATERIALS AND METHODS

Subjects
All procedures were performed with approval from the institutional review board and written subject consent. A total of 47 subjects participated, with the control group (n = 17; age, 41. 
MRI Protocol
All experiments were performed on a 3-T whole-body scanner (MAGNETOM Verio; Siemens Healthcare, Erlangen, Germany) equipped with high-performance gradient coils (45 mT/m maximum gradient strength, 200 mT/m per milliseconds slew rate). A body array coil was used for transmission, and the spine and body array coils were combined for signal reception. All subjects were examined in the supine position with their feet entering the scanner first. Blood oxygenation level-dependent MRI data were acquired using a breath-hold multiple gradient echo (mGRE) sequence with the following parameters: field of view, 360 Â 245 mm; number of slices, 5; slice thickness, 5.0 mm; matrix size, 256 Â 176; repetition time, 62 milliseconds; number of echoes, 8 equally spaced (3.09-32.3 milliseconds); average, 1; and flip angle, 30 degrees. Blood oxygenation level-dependent MRI measurements were made at baseline. The patient table was moved to administer 20 mg of furosemide intravenous. Postfurosemide data were acquired approximately 15 minutes after the baseline scans. The action of furosemide is to inhibit reabsorptive transport along the medullary thick ascending limb, which increases medullary PO 2 .
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R2* Maps
The 8 images from each mGRE acquisition were used to estimate R2* on a voxel-by-voxel basis, using an offline linear least squares regression. Magnitude images were thresholded at 20 (arbitrary units) to remove values where the R2* is so high that the signal decays into the noise floor in later echoes. These occur in places with large changes in susceptibility such as regions neighboring the large intestines or areas of no signal (background). Typically, this resulted in less than a mean loss of 7% (0.2% median) voxels within an ROI. R2* maps were created for each subject at baseline and after furosemide administration.
Regions of Interest
Two observers defined ROIs in the cortex, medulla, and the entire renal parenchyma for both the left and right kidneys on the first mGRE image of the center slice. Care was taken not to include any voxels from areas near strong susceptibility changes or other artifacts. Tumors and cysts were excluded from the ROIs as well (2 cases). In addition, macroscopic vasculature was removed when it was readily apparent to the observers. However, they represent a very small number of voxels within the whole parenchyma and are thus expected to have a minimal effect on the computed values, even when not completely removed. Cortical ROIs were drawn according to 2 common methods-2 to 3 small ROIs (<100 voxels) and 1 large ROI (>500 voxels) encompassing the vast majority of the cortex (Fig. 1) . Separate ROIs were defined for each subject at baseline and after furosemide administration.
After all, the ROIs were defined, they were copied to the R2* maps to compute the mean value for each region. Regions of interest on baseline images were matched to postfurosemide images when possible but were drawn separately. The parenchyma ROI was used for higher moment analysis in a similar fashion.
Moment Analysis
After manual segmentation of the renal parenchyma, the R2* distributions were analyzed using 4 sample moments (μ 1 , μ 2 , μ 3 , and μ 4 ). The first moment is the sample mean μ 1 , and the next 3 are central moments (computed around the mean). Given the mean μ 1 , for n > 1, the nth central moment of an image, I, containing V voxels, is defined as
In statistics, the first 3 moments after the sample mean are commonly referred to as the standard deviation (μ 2 ), skewness (μ 3 ), and kurtosis (μ 4 ). These can be considered to describe the shape features of the distribution. These names generally refer to standardized moments, which are defined in relation to the normal distribution. The parenchyma distribution is not expected to be normally distributed because of the inclusion of 2 distinct regional distributions; we preferred to use the actual moments as parameters rather than use the standard statistical nomenclature.
These methods reduce the large number of R2* parenchyma samples to a set of numerical values summarizing the shape of the distribution. Thus, each subject had 4 values per stage (baseline and after furosemide administration). Statistical comparisons were performed with this set of data.
Statistical Analysis
Statistically significant changes were assessed between baseline and postfurosemide R2* measurements, separately in control and CKD groups, for each of the regions. A Wilcoxon nonparametric test was used for this matched pairs comparison. Control and CKD groups were compared in each region and at each stage for statistically significant differences with a Mann-Whitney U test. To help estimate the effect size for each comparison, we report Cohen's d. The use of effect size in addition to P values has been recommended for scientific reporting. 25 Cohen's d effectively represents the effect size in 3 levels: small, medium, and large corresponding to d values greater than or equal to 0.2, 0.5, and 0.8, respectively. We report values as being pragmatically significant when there is both a substantial effect size (ie, d ≥ 0.5) and statistical significance (ie, P < 0.05). Multiple comparisons were corrected for by applying the Holm-Bonferroni method to limit the familywise error rate in reporting false rejections of the null hypothesis. This correction was applied to each set of regional measurements. Values are reported as the mean (SD) where applicable. All analyses were performed using Python 2.7.2 and the SciPy 0.13.3 module. 26 To assess the effects of variability in the definition of ROIs on the computed values, the intraclass correlation coefficients (ICCs) were evaluated. The ICC will be high when there is little variation between the scores given to each subject by the raters. The ICC values are generally stratified as poor agreement (<0.75), moderate agreement (>0.75), and good agreement (>0.9). The ICCs were determined for the mean FIGURE 1. An example of the variation seen in the mean R2* depending on ROI placement. The left column shows a representative control subject, and the right column shows a CKD subject. The first echo from the mGRE images is used as an anatomical template for placing ROIs. The image appears a bit blurry as it is interpolated to this larger size for viewing purposes. The ROI is then used to find the mean of the corresponding region on the calculated R2* map. Three different ROIs are placed for each region (large cortical and parenchyma ROIs are difficult to see due to the overlap of each region). The mean and standard deviations of each region are shown in the plots. Variation between the ROIs is quite large in the small regions, whereas the larger ones are clearly not as susceptible to differences in exact placement.
value of each region and between the various measures used in the multiple moment method. Figure 1 shows an example of these ROIs and the potential variation in the mean values of the individual ROIs. The mean R2* of the small ROIs can vary considerably depending on their placement, whereas the large cortical and parenchyma ROI show very little change based on the plots.
RESULTS
Comparison of Mean Values
The renal parenchyma mean provides the highest interrater agreement (Table 1, Fig. 2 ). Small ROIs (cortex and medulla) show the least agreement between raters, and the medulla has the lowest interrater agreement of all regions (ICC, 0.76). When we analyzed the control and CKD groups separately, the ICC values were not significantly different, 0.76 for CKD versus 0.80 for control (other regions not shown). Because the large cortex has a higher level of agreement than the small cortex does, it is the only region assessed outside of the comparison of intraclass correlation.
When comparing baseline and postfurosemide mean R2* values, the parenchyma mean shows a significant difference in control subjects (Table 2) . Subjects with CKD also show a change in the medulla and the parenchyma (P < 0.05), but the magnitude of the change is considerably less than in the control group as indicated by d (Table 3) .
When comparing controls and subjects with CKD at baseline, the cortical ROI shows a significant difference between control and CKD subjects, whereas the parenchyma mean does not (Table 4) . However, after furosemide administration, both regional and parenchyma ROIs show a significant difference, with the parenchyma showing the largest effect size (Table 5 ). The cortical effect size decreased from baseline, and the medulla also shows a significant difference.
No significant difference was found between left and right kidneys using any of the traditional ROI analysis technique or between any of the moments (data not shown). Figure 3 illustrates a representative distribution of renal parenchymal R2* values at baseline and after administration of furosemide in a control subject (Tables 4-10) . Clearly, one can visualize differences in these distributions. Consistent with the mean value, the higher moments of the parenchyma data showed similar trends. Table 7 shows that all 4 moments are significantly different after furosemide in the control group. Although there was no significant difference observed at baseline between CKD and control subjects (Table 9 ), postfurosemide data show that the first 2 and the fourth moments are significantly different (Table 10 ). In addition, the ICC-assessed interrater agreement of these moments was comparable to large cortical regions (Table 6 ).
Moment Analysis
DISCUSSION
Comparison of Mean Values
Our results demonstrate that the renal parenchyma mean is highly objective in terms of interrater reliability and is able to detect intrasubject changes after administration of furosemide, a widely used pharmacological maneuver for BOLD MRI studies. It is well known that the observed changes after furosemide are regional, with the medulla showing a large change in R2* while the cortex shows minimal to no change. Despite not segmenting the medulla, this regional change is still detectable. Whether the same trend will be observed with other pharmacological maneuvers will require further work.
The need for including effect size to determine a significant result cannot be understated. Scientific literature has generally placed emphasis on a statistical significance that is based solely on the P value, typically at a significance level of 0.05. However, P < 0.05 does not necessarily mean that the observed difference is of any practical consequence. Even small differences will reach statistical significance provided the sample size is large enough. 25 It is considerably more informative to determine an estimate of the magnitude of the difference and whether it is large enough to differentiate a condition of interest, for example, healthy versus CKD. It has been suggested that the effect size should be reported along with, or in place of, P values. 25, 27 
FIGURE 2.
Mean difference (Bland-Altman) plots depicting the interrater agreement for each ROI region. The medulla shows the highest variation, whereas the parenchyma shows the lowest. In addition, the large cortex shows a lower level of variation than the small cortex does. Previous reports have suggested that an effect size of 0.5 could be considered a medium effect and 0.8 considered as a large effect. In this report, we have used P < 0.05 and d > 0.5 to imply a pragmatic notion of significance. Further work may be necessary to reach consensus on what value would be optimal for specific applications. Cortical R2* values were significantly higher in subjects with CKD (Table 4) . Although the mean parenchyma R2* values at baseline did not show a difference between the groups, when evaluated after furosemide administration, all regions were found to be significantly different. The parenchyma mean actually showed a larger effect size than the cortex at this stage or at baseline. Postfurosemide data combine the differences in cortical R2* values and the responses to furosemide in the medulla between the groups of subjects.
Physiological Interpretation
The mean R2* value (or first moment) of the parenchyma and medulla demonstrated significant changes after furosemide administration in control subjects. The observed medullary changes in healthy controls are consistent with several prior reports. 7, 10, 28, 29 The mean R2* value of the parenchyma would be a weighted mean of the cortical and medullary compartments. This results in a smaller effect size (d = 0.84) compared with the medulla (d = 1.59). However, the ability to detect these changes without regional segmentation indicates that the contributions (magnitude and voxel count) from the medulla are sufficiently large. Although the response to furosemide in subjects with CKD also reached P < 0.05, the effect sizes were all quite small, indicating a considerably smaller change in R2*. This trend is consistent with a recent report. 10 The ability to detect differences based on the renal parenchyma without a priori knowledge of regional anatomy greatly simplifies image analysis and is expected to be beneficial in comparing data from different institutions. R2* is used as a surrogate for oxygenation due to its sensitivity to the saturation of hemoglobin. However, this depends on both oxygen delivered and oxygen consumed. Furosemide provides a method to reduce the local oxygen consumption in the medulla in healthy functioning kidneys and results in a higher blood oxygenation, observed as a decrease in R2*. Prior studies have captured these differences by evaluating ΔR2* after furosemide with significantly lower changes in subjects with CKD. 30 Our results with analyzing postfurosemide R2* distributions of renal parenchyma demonstrate an alternative way of capturing the relative differences in response to furosemide. This is most probably related to the opportunistic leveraging of both the increased cortical R2* in CKD and a lower response to furosemide in the medulla. The chronic hypoxia model suggests that subjects with progressive CKD may exhibit higher renal hypoxia. 31 In addition, it is estimated that only 1 in 3 patients at stage 3 have progressive CKD. 31 Thus, it is possible that the differences observed between subjects with CKD and healthy controls are smaller than they would be if the group assessed in this study was restricted to just progressors. To date, no study assessing renal oxygenation has sought to identify or has identified subjects with progressive CKD.
Multiple Moment Analysis
By looking at higher moments, we were able to capture more changes in the shape of the R2* distribution than would be possible with only the mean (Tables 7, 8 ). Figure 3 shows a typical case of how the distributions varied between baseline and after furosemide administration in a control subject. The mean or first moment (μ 1 ) provides Tables 4 to 10 . A kernel density plot is used to estimate the empirical distribution and is not sensitive to the bin size like a histogram would be. A kernel density estimate with Gaussian kernels and automatic bandwidth calculation was used to estimate the continuous probability distribution. information regarding the central tendency of the distribution. The second moment (μ 2 ) indicates the spread of the distribution and may be related to the separation of R2* values between the cortical and medullary regions (clearly the spread is lowered after furosemide administration). The third moment (μ 3 ) relates to the skewness of the distribution and may indicate the relative strength of each compartment (also lower after furosemide administration). Lastly, the fourth moment (μ 4 ) provides information about the relative magnitude of the tails, the values far from the center of the distribution (clearly this is smaller after furosemide administration). However, it is not yet clear how to interpret these additional parameters in practical terms.
There are some limitations with our study. It is important to note that our healthy control group was not age matched to the CKD group. This was primarily due to logistical challenge of recruiting healthy elderly subjects. Earlier reports have failed to demonstrate any significant differences in cortical R2* values with age. 10 However, contributions from age-related differences might not be ruled out in our observations. A previous study did show that response to furosemide might be blunted in older subjects, 7 possibly accounting for the difference in postfurosemide R2* values between controls and subjects with CKD observed here. In this preliminary study, the CKD group had a heterogenous distribution of eGFRs, etiologies, and medications. In addition, potential movement between baseline and postfurosemide images may shift the region of the kidney being analyzed.
Although the thresholds used for determining significance of our results seem to be appropriate for the context of this work, they will require independent validation to reach consensus.
Use of the renal parenchyma in place of the cortex and medulla has been used in prior reports. Ebrahimi et al 15 modeled the distribution as a 2-compartment model whose applicability is not strictly feasible when there is limited contrast between cortex and medulla, for example, subjects with CKD or in healthy subjects after furosemide administration. Piskunowicz et al 16 did not assume a 2-compartment model, but their approach involves the use of a discrete number of layers, each adding several new parameters to the analysis. Saad et al 14 used a measure of fractional tissue hypoxia from the whole parenchyma as a replacement for individual regional measures from the cortex and medulla. This method used a fixed value of 30 s −1 to separate R2* values into high and low levels of hypoxia. Our approach requires no a priori assumptions. It may be more straightforward to implement, even though custom software will be necessary. Future consensus from the user community may be necessary for optimal choice among the methods for more general acceptance.
In conclusion, our results show that the mean of the renal parenchyma provides a higher interrater agreement when analyzing renal R2* maps than cortical or medullary ROIs. In addition, it shows sufficient sensitivity, in terms of the effect size, when evaluating the response to furosemide, a well-established pharmacologic maneuver in renal BOLD MRI. A new finding is that postfurosemide R2* maps may show more significant differences between controls and subjects with CKD with both a conventional regional ROI analysis and the proposed analysis using the entire renal parenchyma. In addition, by using higher moments, the sensitivity to detecting both intersubject and intrasubject differences could be improved. However, the physiologic interpretation requires further studies and independent validation.
As take home messages, our data support the use of the entire renal parenchyma when analyzing R2* maps from subjects with minimal corticomedullary contrast. Alternately, large cortical ROIs could be used for evaluating baseline differences between different groups of subjects. Even in healthy subjects, the use of both cortical and parenchyma analysis may be preferred for comprehensive and objective evaluation. The limitations of using only P values for significance have been known, but our data further highlight the need to use additional information such as the effect size.
